Rahul D. Ballal

Rahul D. Ballal is a declared insider at 2 companies (chief executive); the most frequent names are Agios Pharmaceuticals, Inc. and Enliven Therapeutics, Inc. Between 28 January 2022 and 18 June 2026, the trades on record add up to 21 filings.

No open-market purchase appears, only 7 sales worth €1.2M. The rest of the record consists of 1 share grant and 13 option exercises.

The newest entry dates from 23 June 2026: an option exercise, in Agios Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.